IDR 400.0
(-1.48%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 26.79 Billion IDR | -64.2% |
2022 | 75.05 Billion IDR | -47.86% |
2021 | 143.94 Billion IDR | 84.07% |
2020 | 78.2 Billion IDR | 80.18% |
2019 | 43.4 Billion IDR | 0.7% |
2018 | 43.09 Billion IDR | 19.77% |
2017 | 35.98 Billion IDR | 3128.66% |
2016 | 1.11 Billion IDR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q3 | 21.08 Billion IDR | 92.7% |
2024 Q1 | 8.45 Billion IDR | 566.54% |
2024 Q2 | 10.94 Billion IDR | 29.34% |
2023 Q2 | 11.08 Billion IDR | 32.65% |
2023 FY | 26.87 Billion IDR | -64.2% |
2023 Q3 | 6.96 Billion IDR | -37.18% |
2023 Q4 | -1.81 Billion IDR | -126.04% |
2023 Q1 | 8.35 Billion IDR | -49.43% |
2022 FY | 75.05 Billion IDR | -47.86% |
2022 Q4 | 16.52 Billion IDR | 98.32% |
2022 Q3 | 8.33 Billion IDR | -59.97% |
2022 Q2 | 20.81 Billion IDR | -29.16% |
2022 Q1 | 29.38 Billion IDR | 7.07% |
2021 Q1 | 26.22 Billion IDR | -60.77% |
2021 FY | 143.94 Billion IDR | 84.07% |
2021 Q4 | 27.44 Billion IDR | -43.81% |
2021 Q3 | 48.84 Billion IDR | 17.87% |
2021 Q2 | 41.43 Billion IDR | 58.0% |
2020 Q2 | 2.37 Billion IDR | 69.48% |
2020 Q1 | 1.4 Billion IDR | -95.97% |
2020 FY | 78.2 Billion IDR | 80.18% |
2020 Q4 | 66.84 Billion IDR | 782.1% |
2020 Q3 | 7.57 Billion IDR | 218.91% |
2019 Q2 | 3.51 Billion IDR | 21.47% |
2019 FY | 43.4 Billion IDR | 0.7% |
2019 Q1 | 2.89 Billion IDR | 0.0% |
2019 Q3 | 2.21 Billion IDR | -37.03% |
2019 Q4 | 34.78 Billion IDR | 1473.2% |
2018 Q1 | 5.69 Billion IDR | 0.0% |
2018 FY | 43.09 Billion IDR | 19.77% |
2017 FY | 35.98 Billion IDR | 3128.66% |
2016 FY | 1.11 Billion IDR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
PT Enseval Putera Megatrading Tbk. | 872.14 Billion IDR | 96.928% |
PT Kimia Farma (Persero) Tbk | -1570.24 Billion IDR | 101.706% |
PT Millennium Pharmacon International Tbk | 105.39 Billion IDR | 74.578% |
PT Soho Global Health Tbk | 438.67 Billion IDR | 93.892% |